• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Bard transvaginal mesh lawsuits begin in February | Legal News

Bard transvaginal mesh lawsuits begin in February | Legal News

May 7, 2012 By MassDevice staff

gavel

 First Bard transvaginal mesh lawsuits to begin in February
The 1st set of lawsuits accusing device maker C.R. Bard (NYSE:BCR) and others of manufacturing defective transvaginal mesh products will hit a federal court in West Virginia next year.

The results could set the tone for lawsuit against fellow mesh-makers Johnson & Johnson (NYSE:JNJ), Endo Pharmaceuticals Holdings (NSDQ:ENDP) and Boston Scientific (NYSE:BSX), also targeted by patient injury lawsuits.

U.S. District Judge Joseph Goodwin will oversee the 1st of about 600 lawsuits claiming that Bard’s Avaulta line of mesh products were "rushed to the market without first being shown to be safe or effective" and resulted in "serious physical and emotional injuries," according to a press release from the law firm of Blasingame, Burch, Garrard & Ashley P.C. 

Bard found itself mired in a mess of lawsuits after dozens of patients asked to join a multi-district federal case against the company for allegedly selling defective and dangerous products – its Avaulta transvaginal mesh.

Consolidated from 21 individual lawsuits in October 2010, the lawsuit includes complaints from women implanted with three different types of Bard mesh: The Avaulta Biosynthetic, the Avaulta Plus and the Avaulta Solo mesh.

The complaints arose as transvaginal mesh gained visibility in the public eye over FDA concerns that it might do more harm than good. The devices are used to treat pelvic organ prolapse, which occurs when internal support structures become so weak or stretched that organs, like the uterus, bladder or bowels, sag from their normal position and bulge or prolapse into the vagina.
Read more

Read more medical device legal news from MassDevice.com

 First Depuy ASR hip lawsuits set for trial in December
Nearly 2 years after Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Orthopaedics recalled it’s troubled ASR metal-on-metal hip implants, the 1st patient injury lawsuits will head to court in December and January. A pair of trials in Nevada and Maryland are scheduled to begin hearings, each involving 3 hip implant recipients alleging that the devices caused more harm than good.

Lawsuits over the metal-on-metal hips have piled up around the world. Hundreds of Australian patients joined a class action lawsuit that some say may top $200 million in damages. The upcoming trials are expected to be a bellwether for how juries will react to lawsuits moving forward.
Read more

 CAO sues Biolase for laser patent infringement
Biolase Technology (NSDQ:BLTI) announced that it received notice of a patent infringement lawsuit filed by CAO Group over Biolase’s ezlase dental diode laser technology. The lawsuit doesn’t include any actual design, features or functions of the ezlase, but mentions specifically the device’s methods for storing excessive fiber, according to a press release.

Biolase CEO Federico Pignatelli was brazenly confident in defending the company’s patent portfolio.

"CAO’s diode is an inferior product manufactured in China," Pignatelli said in prepared remarks. " It is costly, has less laser power and fewer features when compared to ezlase, and it also has a large physical footprint and unpleasant design. We believe CAO, who clearly cannot fairly compete with BIOLASE among the dental community, has instead turned to the court system with this lawsuit, which we strongly believe to be frivolous, in an attempt to exploit us and to try and achieve what it clearly cannot accomplish in the marketplace."

The ezlase system won FDA clearance in 2007, landing additional clearances for tooth whitening and pain relief therapy in 2008 and 2009.

"CAO, an upstart newcomer to our esteemed industry, contends that the ezlase, which has been on the market for more than five years, infringes on what appears to be a narrow patent that received minimal scrutiny from the patent office," Pignatelli said. "We look forward to our day in court."

As of the end of April, Biolase had not yet been served a complain on the lawsuit, according to a press release.
Read more

Filed Under: Legal News, News Well, Patent Infringement, Recalls, Women's Health Tagged With: Biolase, C.R. Bard, CAO Group, depuysynthes, Hips, Johnson and Johnson, Legal Roundup

More recent news

  • Zynex submits laser pulse oximeter to FDA
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub
  • Product liability lawsuits target Medtronic, Boston Scientific spinal cord stim tech
  • GE HealthCare launches new MRI scanner
  • HistoSonics earns first major reimbursement win for non-invasive histotripsy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy